Sign in
Active, not recruitingPhase 3

Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia

Key facts

Who runs it
Geropharm
Where
Russia6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
160 people enrolled
Started
4 Apr 2023
Expected to end
31 Mar 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • GP404141
  • Nplate
Record updated
11 July 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 43 criteriaShow less

Who can take part

  • Signed informed consent to participate in the study
  • male or female
  • Age ≥18 years
  • Diagnosis of primary immune thrombocytopenia (PIT)
  • Duration of PIT at the Screening Visit: for cohort 1: ≥3 months; for cohort 2: ≥6 months
  • PIT therapy with glucocorticosteroids (GCS) for cohort 1: duration of continuous therapy ≥3 months at the Screening Visit or ≥2 courses of pulse therapy during the year before the Screening Visit
  • TPO-RA therapy: for cohort 1: no history of TPO-RA use; for Cohort 2: Use of TPO-RA for ≥12 weeks at the Screening Visit
  • No increase in TPO-RA dose during the 4 weeks preceding the end of screening
  • Blood platelet count: for cohort 1: mean platelet count ≤30×10*9/L, based on the last two measurements 7±2 days apart, each of which had a platelet count ≤35×10*9/L OR steroid dependence, defined as the use of prednisolone at a daily dose of >5 mg (or another corticosteroid at an equivalent dose) for ≥2 months before the Screening Visit to maintain a platelet count ≥30×10*9/L OR to prevent bleeding; for cohort 2: platelet count ≥50×10*9/ml for ≥6 weeks out of the last 8 weeks of follow-up with platelet counts every 7±2 days and no emergency treatment for severe hemorrhagic syndrome in the last 12 weeks before the Screening Visit
  • Consent and ability to comply with the procedures of the Protocol, as well as the prohibitions and restrictions provided for by the Research Protocol

Who cannot take part

  • Unpromising treatment with romiplostim in the opinion of the Researcher
  • Splenectomy <24 weeks prior to the Screening Visit or planned splenectomy during the study
  • Treatment with rituximab within the 14 weeks preceding the Screening Visit, or planned treatment with rituximab during the study
  • Treatment with intravenous immunoglobulin or anti-D immunoglobulin during the 2 weeks preceding the Screening Visit, or planned use during the study
  • Therapy with hematopoietic growth factors during the 4 weeks preceding the Screening Visit, or their planned use during the study
  • Therapy with alkylating chemotherapy drugs during the 8 weeks preceding the Screening Visit, or their planned use during the study
  • Participation in a clinical trial of an investigational drug or investigational medical device within 4 weeks or 5 half-lives (whichever is longer) preceding the Screening Visit
  • Uncontrolled concomitant diseases of internal organs
  • use of combined oral contraceptives or menopausal hormone therapy
  • positive titer of antiphospholipid antibodies
  • Major surgery ("major surgery") within 8 weeks preceding the Screening Visit, or incomplete recovery from surgery at the Screening Visit
  • Hypersensitivity to romiplostim
  • History of TPO-RA use: for cohort 1: any TPO-RA; for cohort 2: any TPO-RA, with the exception of romiplostim and eltrombopag
  • Secondary immune thrombocytopenia in the following diseases: autoimmune thyroiditis, systemic lupus erythematosus (SLE), antiphospholipid syndrome (APLS), lymphoproliferative diseases, drug-mediated, viral origin (herpes viruses, HIV, chronic viral hepatitis)
  • Diseases of the hematopoietic system accompanied by thrombocytopenia (for example, acute leukemia, aplastic anemia, myelodysplastic syndrome, lymphoproliferative diseases)
  • Arterial thrombosis (for example, myocardial infarction, acute cerebrovascular accident) within 1 year preceding the Screening Visit
  • History of venous thrombosis
  • High risk of venous thrombosis and thromboembolism, defined as the presence of at least three of the following risk factors:
  • diabetes
  • arterial hypertension requiring therapy
  • HIV infection
  • Viral hepatitis B or C
  • Oncological and/or oncohematological disease beyond the stage of complete 5-year remission at the Screening Visit
  • A history of mental disorders that do not allow you to adequately assess your behavior and follow the conditions of the study protocol
  • hypercholesterolemia (>240 mg/dl or >13 mmol/l)
  • Use of other medicines listed in section 5.3.3. of this study protocol
  • Hereditary thrombocytopenia
  • Metastatic bone marrow lesions
  • smoking
  • hypertriglyceridemia
  • Pregnancy or lactation in women
  • Hospitalization for any reason planned during the patient's participation in the study
  • Alcoholism. Alcoholism or consumption of alcohol in quantities exceeding for men: 14 units. per week (on average); for women: 7 units. per week (on average)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to demonstrate equivalent efficacy and comparable safety of the drug GP40141 (GEROPHARM, Russia) in comparison with the drug Nplate® (Amgen, the Netherlands). the main questions are

Read full original descriptionShow less

1. Assess the effectiveness of GP40141 in comparison with Nplate®. 2. Assess the immunogenicity of GP40141 in comparison with the drug Nplate®. 3. Assess the safety of GP40141 in comparison with the drug Nplate®. 4. Assess the safety of changing romiplostim and eltrombopag to GP40141. 5. Assess the pharmacokinetic parameters of the study drugs in patients with primary immune thrombocytopenia.

Participants divided into 2 cohorts (naïve or treated with a thrombopoietin receptor agonist) will receive romiplostim and platelet response, immune response and adverse reactions will be assessed.

The 2 groups in the trial

  • GP40141Treatment being tested

    Lyophilized powder for solution 250 mcg in vials is diluted in sterile water for injection to a concentration of 500 mcg/ml. Administer once a week. Cohort 1 Starting dose of romiplostim is 1 mcg/kg actual body weight. The weekly dose of romiplostim is increased in increments of 1 mcg/kg body weight until the patient's platelet count reaches ≥50 x 10\*9/L. Platelet counts are assessed weekly. Cohort 2 * For subjects receiving Nplate®, a switch to GP40141 at an equivalent dose is recommended 7±2 days after the last Nplate® administration. The transition is equidosal since the drugs contain the same active ingredient. * For patients receiving eltrombopag or Etrombopag-29F® (Pharmproekt, Russia)), it is recommended to switch to GP40141 at an initial dose of 1 mcg/kg the day after the last dose of eltrombopag. The maintenance dose, dose adjustment, and maximum dose are consistent for both cohorts. Duration of therapy with study drugs will be 26 weeks.

    Treatment: GP404141

  • NplateExisting treatment, for comparison

    Lyophilized powder for solution 250 mcg in vials is diluted in sterile water for injection to a concentration of 500 mcg/ml. Administer once a week. Cohort 1 Starting dose of romiplostim is 1 mcg/kg actual body weight. The weekly dose of romiplostim is increased in increments of 1 mcg/kg body weight until the patient's platelet count reaches ≥50 x 10\*9/L. Platelet counts are assessed weekly. Cohort 2 Initial dose: • For patients receiving eltrombopag or Etrombopag-29F® (Pharmproekt, Russia)), it is recommended to switch to at Nplate® initial dose of 1 mcg/kg the day after the last dose of eltrombopag. The maintenance dose, dose adjustment, and maximum dose are consistent for both cohorts. Duration of therapy with study drugs will be 26 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multicenter Randomized Controlled Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) Compared With Nplate® (Amgen, the Netherlands) in Patients With Persistent or Early Immune Thrombocytopenia
Publications
Record updated
11 July 2024